NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06355024 2025-07-18
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Fudan University
Phase 2 Completed
NCT06102824 2024-11-25
ORIENTA
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT06355037 2024-07-08
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Fudan University
Phase 2 Recruiting
NCT01446016 2023-01-23
CAT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT03057600 2022-09-28
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
Calithera Biosciences, Inc
Phase 2 Completed
NCT02685306 2017-03-09
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals
Phase 2 Withdrawn
NCT00475670 2014-09-15
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Completed